Biocytogen Pharmaceuticals Co. Ltd. (2315)

Overview

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a pioneering biotechnology enterprise focused on the discovery and development of antibody-based therapeutics. Established in 2009 and headquartered in Beijing, China, the company operates on a global scale, with activities spanning the People's Republic of China, the United States, and other international markets. The core mission of Biocytogen is to address unmet medical needs through the development of innovative treatment options for a variety of diseases, including oncology, autoimmune disorders, inflammation, metabolic diseases, and more. The company has established itself as a leader in its field, leveraging cutting-edge technologies and scientific approaches to foster advancements in antibody drug development.

Products and Services

YH003: A humanized IgG2 agonistic monoclonal antibody aiming at CD40, a costimulatory protein on antigen-presenting cells. This product is designed to enhance immune responses against cancer cells.

YH001: A humanized anti-CTLA-4 IgG1 monoclonal antibody. As one of the pioneering checkpoints inhibitors, it is developed to block CTLA-4, a protein that downregulates the immune system, thus enhancing the body's ability to fight cancer.

YH002: A recombinant humanized IgG1 antibody targeting the human OX40 receptor. By stimulating this receptor, YH002 is intended to promote a more effective immune response against cancer cells.

H004: A humanized IgG1 anti-4-1BB Agonists. This product focuses on activating the 4-1BB pathway which plays a crucial role in the survival and proliferation of T cells, aiming to reinforce the body's anti-tumor immunity.

YH005: An anti-Claudin 18.2 antibody developed to target and attack cancer cells expressing the Claudin 18.2 protein, which is often found in gastric and other types of cancer.

YH008: An anti-PD-1/CD 40 bi-specific antibody. This innovative product combines the mechanisms of PD-1 inhibition and CD40 activation in a single molecule, offering a novel approach for the treatment of solid tumors.

Pre-clinical Products: Biocytogen is also developing a range of pre-clinical products, including YH012 and YH013 for solid tumors treatment; YH015, a human IgG1 antagonistic monoclonal antibody for CD40 treatment; YH016 for oncology; and YH017 for autoimmunity. Each of these pre-clinical candidates aim to address different mechanisms and pathways related to disease progression, signaling Biocytogen's commitment to expanding its portfolio of innovative treatments.

In addition to its portfolio of antibody-based therapeutics, Biocytogen has entered a collaboration with CtM Biotech (Shanghai) Co., Ltd. to co-develop a TCR-mimic Antibody-based Multi-Specific T Cell Engager targeting WT1/HLA-A02. This partnership highlights Biocytogen's strategies to foster collaboration and leverage complementary expertise to develop next-generation immunotherapies.